Zealand Pharma

Declaration of Voting Results & Voting Rights Announcements • Dec 31, 2015

Copenhagen, 2015-12-31 10:51 CET (GLOBE NEWSWIRE) -- Copenhagen, 31 December
2015 - In accordance with Section 6 of the Danish Statutory Order on Issuers'
Disclosure Obligations, Zealand announces the total number of shares and voting
rights in the company at the end of a calendar month in which changes to the
share capital have occurred.

With reference to Company Announcement no. 52 / 2015 dated 4 December 2015
informing of an increase in the share capital and the voting rights after
exercise of employee warrants, the table below provides the total number of
shares and voting rights in Zealand as of 31 December 2015.

Date Total number of shares Share capital Total number of
(nominal value of DKK 1 (nominal value in votes
each) DKK)

---

31 Dec 24,352,769 24,352,769 24,352,769
2015

---

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and
Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company
with leading-edge scientific expertise in turning peptides into medicines.
Zealand has a growing proprietary pipeline of novel specialty drug candidates
and a mature portfolio of products and projects under license collaborations
with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
analogue for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® by Sanofi and under regulatory review in the US. The license agreement
with Sanofi covers also LixiLan, which is a single-product combination of
lixisenatide and insulin glargine (Lantus®). LixiLan has been submitted for
regulatory priority review in the US and regulatory submission is expected in
the EU in Q1 2016.

The proprietary pipeline includes; danegaptide for ischemic reperfusion
Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II
development; and the stable glucagon analogue, ZP4207, in Phase II preparation
both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose
use to treat and control mild to moderate hypoglycemia; ZP2929 for
diabetes/obesity in Phase I; as well as several preclinical peptide
therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information
about Zealand’s business and activities, please visit: www.zealandpharma.com or
follow us on Twitter @ZealandPharma